Tabor Asset Management LP Takes $452,000 Position in LENSAR, Inc. (NASDAQ:LNSR)

Tabor Asset Management LP acquired a new stake in LENSAR, Inc. (NASDAQ:LNSR - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 32,000 shares of the company's stock, valued at approximately $452,000. Tabor Asset Management LP owned 0.27% of LENSAR at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Huntleigh Advisors Inc. purchased a new position in shares of LENSAR during the first quarter worth approximately $1,069,000. Renaissance Technologies LLC increased its position in LENSAR by 13.3% during the 4th quarter. Renaissance Technologies LLC now owns 348,891 shares of the company's stock valued at $3,119,000 after purchasing an additional 40,946 shares during the period. Draper Asset Management LLC bought a new position in LENSAR in the 1st quarter worth $565,000. Finally, Geode Capital Management LLC raised its holdings in LENSAR by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 106,058 shares of the company's stock worth $948,000 after purchasing an additional 5,627 shares in the last quarter. 40.15% of the stock is owned by hedge funds and other institutional investors.

LENSAR Price Performance

Shares of NASDAQ:LNSR traded up $0.07 during trading on Monday, hitting $13.17. The company's stock had a trading volume of 19,714 shares, compared to its average volume of 93,750. The company has a 50-day moving average of $13.17 and a 200-day moving average of $12.55. LENSAR, Inc. has a 12 month low of $3.50 and a 12 month high of $17.31. The firm has a market cap of $155.22 million, a price-to-earnings ratio of -2.72 and a beta of 0.50.

LENSAR (NASDAQ:LNSR - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($2.32) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($2.16). The firm had revenue of $11.53 million for the quarter, compared to the consensus estimate of $13.40 million. LENSAR had a negative return on equity of 737.30% and a negative net margin of 99.17%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. BTIG Research downgraded shares of LENSAR from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 24th. Lake Street Capital reissued a "hold" rating and set a $15.00 price objective (down from $16.00) on shares of LENSAR in a research report on Monday, March 24th.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.